Previous 10 | Next 10 |
I covered Athersys' ischemic stroke trial earlier. The stock has fallen as a result of issues with this trial. However, Covid-induced ARDS is its most important indication, where it has market-leading positive data. For further details see: Athersys: COVID-ARDS Is The Co...
Gainers: Greenland Technologies Corporation (NASDAQ:GTEC) +71%. Longeveron (NASDAQ:LGVN) +37%. Aurora (NASDAQ:AUR) +31%. Bakkt (NYSE:BKKT) +26%. FedNat Holding Company (NASDAQ:FNHC) +18%. UWM Holdings Corporation (NYSE:UWMC) +18%. SCYNEXIS (NASDAQ:SCYX) +16%. Kornit (NASDAQ:KRNT) +15%. Aspira...
Gainers: Longeveron (NASDAQ:LGVN) +36%, SCYNEXIS (NASDAQ:SCYX) +16%, Context Therapeutics (NASDAQ:CNTX) +15%, Akoya Biosciences (NASDAQ:AKYA) +15%, Aspira Women's Health (NASDAQ:AWH) +15%. Losers: Connect Biopharma (NASDAQ:CNTB) -54%, Flora Gr...
Image source: The Motley Fool. Athersys (NASDAQ: ATHX) Q3 2021 Earnings Call Nov 15, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Athersys (ATHX) Q3 2021 Earnings Call Transcript
Athersys, Inc. (ATHX) Q3 2021 Earnings Conference Call November 16, 2021, 4:30 PM ET Company Participants Karen Hunady – Director of Corporate Communications and Investor Relations B.J. Lehmann – President, Chief Operating Officer, Interim CEO Ivor Macleod – Chief Financi...
Athersys (NASDAQ:ATHX): Q3 GAAP EPS of -$0.07 beats by $0.04. Revenue of $4.79M Press Release Ended the third quarter with $49.7 million of cash and cash equivalents. For further details see: Athersys EPS beats by $0.04
Positive topline data for ARDS study and completion of enrollment in Japan ischemic stroke study are important milestones for development and potential commercialization of MultiStem ® cell therapy Management to host conference call at 4:30 pm EST today ...
Athersys (NASDAQ:ATHX) is scheduled to announce Q3 earnings results on Monday, November 15th, after market close. The consensus EPS Estimate is -$0.11 (flat Y/Y) and the consensus Revenue Estimate is $0.06M (-33.3% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 0 ...
Athersys reports that HEALIOS K.K. (Healios), its development and commercial partner in Japan, provided an update earlier this morning regarding its clinical programs for acute respiratory distress syndrome (ARDS) and ischemic stroke involving MultiStem ® (HLCM051, invimestroce...
Conference being held Oct. 12th to 14th, 2021 in Carlsbad Athersys, Inc. (NASDAQ: ATHX) announced today that Dr. Robert W. Mays and Mr. William (B.J.) Lehmann will participate in person at the annual Cell & Gene Meeting on the Mesa Hybrid Conference to be held Octobe...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...